论文部分内容阅读
目的探讨缬沙坦治疗扩张型心肌病的可行性和安全性。方法收集整理我院收治的50例扩张性心肌病患者,将其分为治疗组和对照组各25例,在治疗的过程中,治疗组患者使用常规治疗联合缬沙坦治疗;对照组的患者仅使用常规治疗,在治疗结束之后对两组患者的治疗效果进行统计分析。结果治疗组患者在治疗之后,患者的心脏功能检测明显优于对照组患者,两组患者之间的情况差异有统计学意义,(P<0.05),两组患者的治疗效果差异存在统计学意义,P<0.05。结论在治疗扩张性心肌病的过程中,可以使用缬沙坦辅助治疗,有效的提高患者的治疗效果,改善患者的心功能,在临床治疗过程中可以进行推广使用。
Objective To investigate the feasibility and safety of valsartan in the treatment of dilated cardiomyopathy. Methods Totally 50 patients with dilated cardiomyopathy admitted to our hospital were divided into treatment group and control group of 25 cases. During the treatment, patients in treatment group were treated with conventional therapy combined with valsartan. Patients in control group Only conventional treatment was used, and after the treatment was completed, the treatment effects of both groups were statistically analyzed. Results After treatment, the cardiac function of patients in the treatment group was significantly better than that in the control group, and the difference between the two groups was statistically significant (P <0.05). There was a statistically significant difference in the therapeutic effect between the two groups , P <0.05. Conclusion In the treatment of dilated cardiomyopathy, valsartan can be used adjuvant therapy to effectively improve the therapeutic effect of patients and improve the patient’s cardiac function, which can be promoted and used in clinical treatment.